QUEBEC CITY, Sept. 19 /CNW Telbec/ - AEterna Zentaris Inc. (TSX: AEZ;
NASDAQ: AEZS), a growing global biopharmaceutical company focused on endocrine
therapy and oncology, announced today that it has entered into an agreement
with RBC Capital Markets providing for the sale on a bought-deal basis and
distribution to the public of 3,485,000 subordinate voting shares held by it
in its subsidiary, Atrium Biotechnologies Inc. (Atrium), representing 24% of
AEterna Zentaris' ownership interest in Atrium, at a price of Cdn$15.80 per
share. Atrium Biotechnologies Inc. (TSX: ATB) is a leading developer,
manufacturer and marketer of science-based products for the cosmetics,
pharmaceutical, chemical and nutrition industries.
